Navigation Links
Footrot vaccine closer than ever
Date:7/1/2008

Monash University scientists have started clinical trials to find a successful vaccine against footrot in sheep.

The trials have been made possible with funding of $663,000 from Australian Wool Innovation (AWI)

The trials over three years are taking place at Monash University's Australian Research Council Centre of Excellence in Structural and Functional Microbial Genomics and the University of Sydney.

Chief investigator Professor Julian Rood said it was an exciting development for his team of researchers.

"The trials are the culmination of 8 years of collaborative work on the pathogenic bacterium which causes footrot, Dichelobacter nodosus. We have determined the bacterium's complete DNA sequence, which was then analysed to identify proteins that are potentially exposed on the surface of the causative bacterium and therefore more likely to elicit an immune response," Professor Rood said.

"The approach, called reverse vaccinology, identified 90 proteins in the footrot bacterium that are potential antigens for a new cross-protective vaccine. This funding will allow us to pinpoint those proteins that will target the disease in a vaccine application," Professor Rood said.

"Our Centre's approach has made significant inroads in the development of a novel vaccine for footrot. The trialling process involves treating sheep with purified surface expressed proteins to assess whether they produce an immune response. The AWI funding means the development of a marketable vaccine is likely to happen a lot sooner. Ideally, this could be within a decade."

Australian Wool Innovation's Program Manager of Animal Health, Productivity and Welfare, Dr Johann Schrder said footrot has long been the bane of Australian woolgrowers and prime lamb producers.

"While many improvements have been made over the years in its control, and we have a very good understanding of measures to limit its impact on production, this avenue of research holds great promise," Dr Schrder said.


'/>"/>

Contact: Samantha Blair
samantha.blair@adm.monash.edu.au
61-399-034-841
Monash University
Source:Eurekalert

Related biology news :

1. Possible hepatitis C vaccine
2. Study by Pittsburgh researchers identifies possible vaccine target for chlamydia
3. New nanoparticle vaccine is more effective but less expensive
4. Flu vaccine in painless skin patches under development at Emory, Georgia Tech with NIH grants
5. Influenza vaccine causes weaker immune response for children of rural Gabon than in semi-urban areas
6. An Alzheimers vaccine?
7. Penn researchers find monkeys able to fend off AIDS-like symptoms with enhanced HIV vaccine
8. CWRU School of Medicine has evidence vaccine against malaria will reduce disease
9. HIV isolate from Kenya provides clues for vaccine design
10. Iowa State researchers look for smaller, cheaper, 1-dose vaccines
11. Vaccine for Ebola virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... e-Government, Public Safety, HealthCare, and Finance sectors announced today that Leaders ... to implement and deploy a community-based supportive services program to reduce ... , further expanding its presence in the state. ... This new program, which is expected ...
(Date:12/16/2016)...   IdentyTechSolutions America LLC , a leading ... and a cutting-edge manufacturer of software and hardware ... seamless, integrated solutions that comprise IDT biometric readers ... provide IdentyTech,s customers with combined physical identification and ... and theft. "We are proud to ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017  Protagonist Therapeutics, Inc. ... it has initiated a global Phase 2b induction ... peptide that targets alpha4beta7 integrin. The aim of ... to evaluate the safety/tolerability and efficacy of PTG-100 ... moderate to severe active disease. ...
(Date:1/16/2017)... ... January 16, 2017 , ... Attagene , a Research ... U.S. Small Business Administration. The Tibbetts Award honors the Small Business Innovation ... and are considered the best of the best from the thousands of firms ...
(Date:1/13/2017)... -- Research and Markets has announced the addition of ... to 2021" report to their offering. ... The biosimilars market is expected to ... 2016, at a CAGR of 26.3%. The global ... and application. Factors such as rising incidence of various diseases, increasing ...
(Date:1/13/2017)... Island, NY (PRWEB) , ... January 13, 2017 ... ... teamed up with several companies to offer its customers three new solutions for ... probe would come in handy if a customer has an oddly-shaped sample that ...
Breaking Biology Technology: